Tags

Type your tag names separated by a space and hit enter

MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark.
Int Forum Allergy Rhinol. 2019 04; 9(4):388-395.IF

Abstract

BACKGROUND

Allergic rhinitis (AR) control is a priority in the European Union (EU), and Allergic Rhinitis and its Impact on Asthma (ARIA) has endorsed a visual analogue scale (VAS) as the new language of AR control. This study evaluated the effectiveness of MP-AzeFlu (Dymista®, antihistamine [azelastine], and intranasal corticosteroid [fluticasone propionate]) using a VAS in real-life clinical practice in Denmark.

METHODS

The multicenter, prospective, non-interventional study included 170 patients (≥12 years) with ARIA-defined moderate-to-severe AR prescribed MP-AzeFlu. Patients assessed symptom severity using a VAS (0 to 100 mm) on days 0, 1, 3, and 7 and after ∼14 days of MP-AzeFlu use. On day 3, patients assessed their disease as well controlled, partly controlled, or uncontrolled. Proportions of patients achieving VAS score cutoffs (well-controlled, partly controlled) were also calculated.

RESULTS

MP-AzeFlu reduced mean ± standard deviation VAS score from 67.1 ± 19.3 mm at baseline to 28.4 ± 23.7 mm on the last day, a reduction of 38.8 ± 27.3 mm. At day 3, 85.6% of patients considered their symptoms to be partly or well controlled. Effectiveness was consistent across disease severity, phenotype (seasonal, perennial, or combined AR), and patient age. Respectively, 28.2%, 44.2%, 61.6%, and 71.4% of patients achieved ≤38 mm well-controlled VAS score cutoff on days 1, 3, and 7, and the last day.

CONCLUSION

MP-AzeFlu provided effective, rapid, and sustained symptom control in a real-life setting among patients from Denmark. These results align with EU and ARIA objectives and support the effectiveness of MP-AzeFlu for the treatment of AR in real life.

Authors+Show Affiliations

Specialist Centre, Vejle, Denmark.Specialist Centre, Hjørring, Denmark.Specialist Centre, Tåstrup, Denmark.

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30659752

Citation

Haahr, Peter A., et al. "MP-AzeFlu Provides Rapid and Effective Allergic Rhinitis Control: Results of a Non-interventional Study in Denmark." International Forum of Allergy & Rhinology, vol. 9, no. 4, 2019, pp. 388-395.
Haahr PA, Jacobsen C, Christensen ME. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. Int Forum Allergy Rhinol. 2019;9(4):388-395.
Haahr, P. A., Jacobsen, C., & Christensen, M. E. (2019). MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. International Forum of Allergy & Rhinology, 9(4), 388-395. https://doi.org/10.1002/alr.22258
Haahr PA, Jacobsen C, Christensen ME. MP-AzeFlu Provides Rapid and Effective Allergic Rhinitis Control: Results of a Non-interventional Study in Denmark. Int Forum Allergy Rhinol. 2019;9(4):388-395. PubMed PMID: 30659752.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. AU - Haahr,Peter A, AU - Jacobsen,Claus, AU - Christensen,Maria E, Y1 - 2019/01/19/ PY - 2018/02/28/received PY - 2018/11/05/revised PY - 2018/11/13/accepted PY - 2019/1/20/pubmed PY - 2020/2/1/medline PY - 2019/1/20/entrez KW - MP-AzeFlu KW - MP29-02 KW - azelastine KW - dymista® KW - fluticasone propionate KW - perennial allergic rhinitis KW - seasonal allergic rhinitis SP - 388 EP - 395 JF - International forum of allergy & rhinology JO - Int Forum Allergy Rhinol VL - 9 IS - 4 N2 - BACKGROUND: Allergic rhinitis (AR) control is a priority in the European Union (EU), and Allergic Rhinitis and its Impact on Asthma (ARIA) has endorsed a visual analogue scale (VAS) as the new language of AR control. This study evaluated the effectiveness of MP-AzeFlu (Dymista®, antihistamine [azelastine], and intranasal corticosteroid [fluticasone propionate]) using a VAS in real-life clinical practice in Denmark. METHODS: The multicenter, prospective, non-interventional study included 170 patients (≥12 years) with ARIA-defined moderate-to-severe AR prescribed MP-AzeFlu. Patients assessed symptom severity using a VAS (0 to 100 mm) on days 0, 1, 3, and 7 and after ∼14 days of MP-AzeFlu use. On day 3, patients assessed their disease as well controlled, partly controlled, or uncontrolled. Proportions of patients achieving VAS score cutoffs (well-controlled, partly controlled) were also calculated. RESULTS: MP-AzeFlu reduced mean ± standard deviation VAS score from 67.1 ± 19.3 mm at baseline to 28.4 ± 23.7 mm on the last day, a reduction of 38.8 ± 27.3 mm. At day 3, 85.6% of patients considered their symptoms to be partly or well controlled. Effectiveness was consistent across disease severity, phenotype (seasonal, perennial, or combined AR), and patient age. Respectively, 28.2%, 44.2%, 61.6%, and 71.4% of patients achieved ≤38 mm well-controlled VAS score cutoff on days 1, 3, and 7, and the last day. CONCLUSION: MP-AzeFlu provided effective, rapid, and sustained symptom control in a real-life setting among patients from Denmark. These results align with EU and ARIA objectives and support the effectiveness of MP-AzeFlu for the treatment of AR in real life. SN - 2042-6984 UR - https://www.unboundmedicine.com/medline/citation/30659752/MP_AzeFlu_provides_rapid_and_effective_allergic_rhinitis_control:_results_of_a_non_interventional_study_in_Denmark_ L2 - https://doi.org/10.1002/alr.22258 DB - PRIME DP - Unbound Medicine ER -